How to reconstitute Sermorelin: mixing and storage
An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
Also called: Sermorelin acetate, Geref, GHRH(1-29)-NH2, GRF(1-29)-NH2, Groliberin.
GHRH analogues · Growth hormone-releasing hormone receptor agonist.
Comes as: Lyophilized powder for injection, Compounded sublingual troches, community-reported.
Mixed with: Historical Geref used Sodium Chloride Injection. Community reports use bacteriostatic water; these are different preparations..
Common vial sizes: 5, 10 mg. Common water amounts: 1, 2 mL.
- Community report: 5 mg with 2 mL bacteriostatic water; vial size and water volume describe concentration, not dose.
- Historical US Geref vials were 0.5 or 1 mg, mixed with 0.5–1 mL saline. These instructions do not validate modern multi-dose vials.
- Do not use a cloudy or visibly contaminated solution. Clear liquid does not prove sterility.
- No universal 28-day or 30-day stability claim is established for all compounded sermorelin products.
- Another community comment reported a 10 mg vial mixed with 1 mL. These reports do not validate vial contents or stability.
Before mixing: Historical Geref label: refrigerate at 2–8°C. Compounded preparations require their own storage instructions.
After mixing: Historical Geref was used immediately and leftovers discarded. Community four-week refrigerator use is not validated stability.
Related to Sermorelin
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Search Results - (emc), 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks, 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Xcel Research LLC - 694608 - 12/10/2024, 2024
- Innoveix Pharmaceuticals Inc - 624782 - 01/26/2022, 2022
- Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 2013
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
- Geref (Seristim), 2005
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.